Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.64 |
| ▸ | JAK2 | O60674 | 3/20 | 0.57 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290529 | 0.89 | JAK1 (0.79) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL24188718 | 0.89 | JAK1 (0.79) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL30622212 | 0.89 | JAK1 (0.79) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL24188841 | 0.89 | JAK1 (0.79) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL12385471 | 0.82 | JAK1 (0.65) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL2295441 | 0.82 | JAK1 (0.65) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL2278589 | 0.81 | JAK1 (0.86) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL2292443 | 0.79 | JAK1 (0.74) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL28630058 | 0.79 | JAK1 (0.62) | JAK1JAK2JAK3AURKAPRKCA | |
| SCHEMBL28616752 | 0.79 | JAK1 (0.62) | JAK1JAK2JAK3AURKAPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516061-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-01-06 | — | — | US | disclosed |
| EP-4520395-A2 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2025-03-12 | — | — | EP | disclosed |
| US-20250026755-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-3856742-B1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2024-10-02 | — | — | EP | disclosed |
| US-12024516-B2 | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-11858933-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11851431-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| US-20230357247-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230339950-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357247-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
| US-20230339950-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
| US-11851431-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
| US-11858933-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
| US-12024516-B2 | Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
| US-20250026755-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.